Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...
Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.
Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.